TITLE

CONTROL OF INTRACTABLE ARRHYTHMIAS BY THE USE OF PROPRANOLOL AND CARDIAC PACING -- REPORT OF TWO CASES

AUTHOR(S)
leon-Sotomayor, Luis
PUB. DATE
December 1974
SOURCE
Angiology;Dec1974, Vol. 25 Issue 11, p729
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
These two cases probably represent some variant of the sick sinus syndrome. In this entity the inappropriate functioning of the sinus node lead to slow and rapid dysrhythmia, although other possible factors may have also contributed to the arrhythmias. The use of the transvenous ventricular demand pacemaker in combination with propranolol and procainamide was able to produce synchronization of the inappropriately functioning sinus node and electronically induced parasystoles. Correction of the intractable arrhythmia was obtained by these means without producing signs and symptoms of cardiac decompensation in patients that have been in overt heart failure. The positive ionotropic action of digitalis and the prevention of the development of sinus bradycardia by the use of the demand pacemaker, set at a more physiological heart rate, minimized the decrease in cardiac output otherwise caused by the use of beta blockade drugs. Propranolol offers an additional advantage when used as an antiarrhythmic agent in patients with poor renal function since the drug is metabolized by the liver to a cardiac inactive compound.
ACCESSION #
16357903

 

Related Articles

  • CLINICAL STUDIES OF NORPACE (Part III). Kalmansohn, Robert G. // Angiology;Jan1975 Part 2, Vol. 26, p137 

    Examines the effectiveness of Norpace therapy among patients who had been on antiarrhythmic agents. Indications of toxicity in anticholinergic effects; Medical history of the patients; Use of oral Norpace in controlling ventricular tachycardia.

  • FDA actions.  // Neurology Alert;Feb2012 Pharmacology, p2 

    The article reports on drug approvals made by the U.S. Food and Drug Administration (FDA) for the manufacture of generic a storvastatin (Lipitor) by Ranbaxy Laboratories and Prevnar 13 vaccine for adults by Wyeth Pharmaceuticals and the restriction in prescriptions of Dronedarone (Multaq), an...

  • flecainide.  // Davis's Drug Guide for Nurses, 10th edition;2007, p523 

    This article presents a nursing guide to the antiarrhythmic agent flecainide. Drug information provided includes pharmacokinetics, contraindications or precautions, adverse reactions or side effects, interactions, route or dosage, and availability. Tambocor is a popular brand of the drug....

  • procainamide.  // Davis's Drug Guide for Nurses, 9th edition;2005, p874 

    Provides information on the antiarrhythmic agent procainamide. Indications and actions of the drug; Pharmacokinetics and side effects of the drug; Administration of the drug.

  • sotalol.  // Davis's Drug Guide for Nurses, 9th edition;2005, p977 

    Deals with the antiarrhythmic agent sotalol. Indications; Pharmacokinetics; Adverse reactions and side effects.

  • moricizine.  // Davis's Drug Guide for Nurses, 9th edition;2005, p708 

    Provides information on moricizine, an antiarrhythmic agent. Pharmacokinetics; Contraindications and precautions; Adverse reactions and side effects; Drug interactions.

  • A New Drug for Rapid Conversion of Atrial Fibrillation. DiMarco, John P. // Clinical Cardiology Alert;May2008, Vol. 27 Issue 5, p37 

    VERNAKALANT IS A NEW INVESTIGATIONAL ANTI-arrhythmic drug. The compound is relatively selective, blocking the early-activating potassium channel and the frequency-dependent sodium channel. Vernakalant has a half-life of two to three hours. This study evaluates the ability of intravenous...

  • Update on Atrial Fibrillation: Restoration of Sinus Rhythm or Ventricular Rate Control? Yi-Gang Li; Hohnloser, Stefan H. // Journal of Cardiovascular Pharmacology & Therapeutics;Jun1998, Vol. 3 Issue 2, p185 

    The article discusses therapeutic alternatives for patients with persistent atrial fibrillation. It summarizes the present knowledge on this clinical problem with particular emphasis on issues such as efficacy of antiarrhythmic drugs to prevent recurrent atrial fibrillation, proarrhythmic...

  • Assessment of the Inactivation Potential of Desethylamiodarone on Human CYP1A1. Elsherbiny, Marwa E.; El-Kadi, Ayman O. S.; Brocks, Dion R. // Drug Metabolism Letters;Jan2010, Vol. 4 Issue 1, p9 

    Desethylamiodarone was reported to inactivate human CYP1A1. To assess this, two protocols were implemented employing dilution and non-dilution of the preincubation mixture. Inactivation studies performed with diluted preincubation mixtures showed no inactivation of CYP1A1 by desethylamiodarone....

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics